A new cell therapy is giving multiple myeloma patients another shot

Bristol Myers Squibb's CAR-T cell therapy arlo-cel met its main goal in a mid-stage trial for people with relapsed multiple myeloma, a blood cancer that has run out of treatment options. The therapy works by reprogramming a patient's own immune cells to hunt down cancer cells. For families facing one of the hardest diagnoses in oncology, a new line of attack matters.